Samer Mouksassi - Concepedia

Author

Samer Mouksassi

Also Known As

M MOUKSASSI, M S Mouksassi, M-samer Mouksassi, M.‐S. Mouksassi, Mohamad Samer Mouksassi, Mohamad-Samer Mouksassi, Mohamad‐Samer Mouksassi, Mouksassi, Mohamad-Samer, M‐S Mouksassi, Samer Mouksassi

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Université de Montréal Certara (United States)Integra LifeSciences (United States)University of Virginia Pharmaceutical Product Development (United States)

About

Samer Mouksassi is an author at Université de Montréal specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	703
2	Public Health	2	2	388
3	Health Sciences	1	1	136
4	Anesthesia	1	1	16
5	Critical Care Medicine	1	1	25

Samer Mouksassi

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics Thi Huyen Tram Nguyen, Samer Mouksassi, Nicholas H. G. Holford, CPT Pharmacometrics & Systems Pharmacology Physiologically-based Pharmacokinetic ModelingPharmacodynamic ModelingData ScienceMisspecified ModelsPublic Health	2016	368
Pharmacokinetic Analysis of Capsaicin After Topical Administration of a High-Concentration Capsaicin Patch to Patients With Peripheral Neuropathic Pain Sunita Babbar, Jean‐Francois Marier, Samer Mouksassi, Therapeutic Drug Monitoring Pain TherapyPain MedicineNeuropathic PainMolecular PainPharmacotherapy	2009	136
Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease Ronald D. Perrone, Samer Mouksassi, Klaus Romero, Kidney International Reports	2017	113
Pharmacokinetics, Safety, and Tolerability of Teduglutide, a Glucagon‐Like Peptide‐2 (GLP‐2) Analog, Following Multiple Ascending Subcutaneous Administrations in Healthy Subjects Jean‐Francois Marier, Martin Béliveau, Samer Mouksassi, The Journal of Clinical Pharmacology	2008	75
Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections Gurudatt Chandorkar, Alan Xiao, Samer Mouksassi, The Journal of Clinical Pharmacology PharmacotherapyAntimicrobial ChemotherapyPopulation PharmacokineticsPharmacodynamic ModelingRenal Function	2014	63
Safety and Population Pharmacokinetic Analysis of Intravenous Acetaminophen in Neonates, Infants, Children, and Adolescents With Pain or Fever Athena F. Zuppa, Gregory B. Hammer, Jeffrey S. Barrett, The Journal of Pediatric Pharmacology and Therapeutics	2011	62
Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma Danièle Ouellet, Nastya Kassir, Joannellyn Chiu, Cancer Chemotherapy and Pharmacology MedicineMelanomaPathologyPopulation PharmacokineticsDermatology	2016	54
Clinical Trial Simulations in Pediatric Patients Using Realistic Covariates: Application to Teduglutide, a Glucagon-Like Peptide-2 Analog in Neonates and Infants With Short-Bowel Syndrome Samer Mouksassi, Jean‐Francois Marier, J Cyran, Clinical Pharmacology & Therapeutics	2009	49
Meropenem in children receiving continuous renal replacement therapy: Clinical trial simulations using realistic covariates Edward Nehus, Samer Mouksassi, Alexander A. Vinks, The Journal of Clinical Pharmacology Fluid OverloadCrrt Prescription CharacteristicsDialysis TherapyPharmacotherapyCritical Care Medicine	2014	25
A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease Ronald D. Perrone, Samer Mouksassi, Klaus Romero, Kidney International Reports Trial EnrichmentTranslational MedicineUrologyDrug Development ToolMedicine	2017	24

Page 1